業績

Publications

研究業績

主要論文

  • 1 Nemoto Y, Morikawa R, Yonemoto Y, Tanaka S, Takei Y, Oshima S, Nagaishi T, Tsuchiya K, Nakamura T, Takenaka K, Ohtsuka K, Chen X, Okazawa H, Okamoto R, Watanabe M, von Andrian UH: Intestinal CD4–CD8ab–TCRab+T cells function as tolerogenic antigen presenting cells in mice.
    Nat Commun. 16: 7072, 2025.
    2 Vieujean S, Schreiber S, Rubin DT, D’Haens G, Reinisch W, Watanabe M, Mehta R, Roblin X, Beales IL, Gietka P, Hibi T, Hospodarskyy I, Ritter T, Genovese MC, Kwon P, Santermans E, Le Brun FO, Barron R, Masior T, Denese S: Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn’s disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 10: 138-153, 2025.
    3 Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik LE, Pittet VEH, Annese V, Park KT, Katsanos KH., Høivik ML, Krznaric Z, Chaparro M, Loftus EV Jr, Lakatos PL, Gisbert JP, Bemelman W, Moum B, Gearry RB, Kappelman MD, Hart A, Pierik M, Andrews JM, Siew C. Ng SC, D’Inca R, Munkholm P: The Costs of Inflammatory Bowel Diseases in High-Income Settings.
    Lancet Gastroenterol Hepatol. 8: 458-492, 2023.
    4 Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T: AJM300 (carotegrast methyl), an oral antagonist of a4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled phase 3 study.
    Lancet Gastroenterol Hepatol. 7: 648-657, 2022.
    5 Panes J, Colombel JF, D’Hanes GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebve J, Finney-Hayward T, Gonzalez YS, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ: Higher vs Standard Adalimumab Induction and Maintenance Dosing Regiments for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
    Gastroenterology. 162: 1891-1910, 2022.
    6 Watanabe S, Kobayashi S, Ogasawara N, Okamoto R, Nakamura T, Watanabe M, Kim BJ, Yui S: Transplantation of Intestinal Organoids into a Mouse Model of Colitis.
    Nature Protocols. 17: 649-671, 2022.
    7 Takenaka K, Fujii T, Kawamoto A, Suzuki K, Shimizu H, Maeyashiki C, Yamaji O, Motobayashi M, Igarashi A, Hanazawa R, Hibiya S, Nagahori M, Saito E, Okamoto R, Ohtsuka K, Watanabe M: Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol., 7: 230-237, 2022.
    8 Nagaishi T, Watabe T, Kotake K, Kumazawa T, Aida T, Tanaka K, Ono R, Ishino F, Usami T, Miura T, Hirakata S, Kawasaki H, Shinkura R, Tsugawa N, Yamada D, Hirayama K, Yoshikawa S, Karasuyama H, Okamoto R, Watanabe M, Blumberg RS, Adachi T：Immunoglobulin A-specific deficiency induces spontaneous inflammation specifically in the ileum.
    Gut. 71: 487-496, 2022.
    9 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group: Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA)： a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 6: 429-437, 2021.
    10 Brian G. Feagan, Silvio Danese, Edward V. Loftus Jr., Séverine Vermeire, Stefan Schreiber, Timothy Ritter, Ronald Fogel, Rajiv Mehta, Sandeep Nijhawan, Radosław Kempiński, Rafał Filip, Ihor Hospodarskyy, Ursula Seidler, Frank Seibold, Ian L.P. Beales, Hyo Jong Kim, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chia-Hsiang Hsueh, Chantal Tasset, Robin Besuyen, Watanabe M, William J. Sandborn, Gerhard Rogler, Hibi T, Laurent Peyrin‑Biroulet: Filgotinib as induction and maintenance therapy for ulcerative colitis: the SELECTION trial.
    Lancet. 397: 2372-2384, 2021.
    11 Takenaka K, Ohtsuka K, Fujii T, Oshima S, Okamoto R, Watanabe M: Deep neural network accurately predicts prognosis of ulcerative colitis using endoscopic images.
    Gastroenterology. 160: 2175-2177, 2021.
    12 Takenaka K, Ohtsuka K, Fujii T, Negi M, Suzuki K, Shimizu H, Oshima S, Akiyama S, Motobayashi M, Nagahori M, Saito E, Matsuoka K, Watanabe M: Development and validation of a Deep Neural Network for accurate evaluation of endoscopic images from patients with ulcerative colitis.
    Gastroenterology. 158: 2150-215-, 2020.
    13 Tsunoda T, Kakinuma S, Miyoshi M, Kamiya A, Kaneko S, Sato A, Tsuchiya J, Nitta S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Sogo T, Komatsu H, Mukouchi R, Inui A, Fujisawa T, Nakauchi H, Asahina Y, Watanabe M: Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 71: 143-152, 2019.
    14 Oshima S, Watanabe M: Genetic and environmental factors drive personalized medicine for Crohn’s disease.
    J Clin Invest. 128: 4758-4760, 2018.
    15 Yui S, Azzolin L, Maimets M, Pedersen M, Fordham R, Hansen S, Guiu J, Alves M, Rundsen C, Johansen J, Li Y, Madsen C, Nakamura T, Wanatabe M, Nielsen O, Schweiger P, Piccolo S, Jensen K: Cellular reprogramming links environmental signaling to YAP/TAZ and tissue regeneration.
    Cell Stem Cell. 22; 35-49, 2018.
    16 Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S, Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T, for the INDIGO Study Group: Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis.
    Gastroenterology 154: 935-947, 2018.
    17 Nibe Y, Oshima S, Kobayashi M, Maeyashiki C, Matsuzawa Y, Otsubo K, Matsuda H, Aonuma E, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Nakada S, Watanabe M: Novel polyubiquitin imaging system, PolyUb-FC, reveals that K33-linked polyubiquitin is recruited by p62/SQSTM1.
    Autophagy. 14: 347-358, 2018.
    18 Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo S, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T: Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer.
    Gastroenterology. 151: 1122-1130, 2016.
    19 Yoshimura N, Watanabe M*, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, Watanabe K, Hibi T. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients with Active Ulcerative Colitis.
    Gastroenterology. 149:1775-1783, 2015. (*Co-first and Corresponding author)
    20 Matsuzawa Y, Oshima S, Takahara M, Maeyashiki C, Nemoto Y, Kobayashi M, Nibe Y, Nozaki K, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Averil Ma, Watanabe M: TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.
    Autophagy. 11:1052-1062,2015.
    21 Fukuda M, Mizutani T, Mochizuki W, Matsumoto T, Nozaki K. Sakamaki Y, Ichinose S, Okada Y, Tanaka T, Watanabe M, Nakamura T: Small intestinal stem cell identity is maintained with functional paneth cells in heterotopically grafted epithelium onto colon.
    Genes Dev. 28: 1752-1757, 2014.
    22 Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Naganuma M, Araki A, Watanabe M: Comparison of Magnetic resonance and balloon enteroscopic examination of deep small intestine in patients with Crohn’s disease.
    Gastroenterology. 147: 334-342, 2014.
    23 Fordham RP, Yui S, Hannan NRF, Madgwick A, Vallier L, Pedersen RA, Nakamura T, Watanabe M, Jensen KB: Establishment of fetal enteric progenitors as a source for transplantation.
    Cell Stem Cell. 13:734-744,2013.
    24 Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N: α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
    Hepatology. 58:1253-1262,2013.
    25 Kiyohashi K, Kakinuma S, Kamiya A, Sakamoto N, Nitta S, Yamanaka H, Yoshino K, Fijiki J, Murakawa M, Kusano-Kitazume A, Shimizu H, Okamoto R, Azuma S, Nakagawa M, Asahina Y, Tanimizu N, Kikuchi A, Nakauchi H, Watanabe M: Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells.
    Hepatology. 57: 2502-2513, 2013.
    26 Nemoto Y, Kanai T, Takahara M, Oshima S, Nakamura T, Okamoto R, Tsuchiya K, Watanabe M: Bonemarrow-mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4+ memory T cells.
    Gut. 62: 1142-1152, 2013.
    27 Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M: Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immunity.
    Hepatology. 57: 46-58, 2013.
    28 Ono Y, Kanai T, Sujino T, Nemoto Y, Kanai Y, Mikami Y, Hayashi A, Matsumoto A, Takaishi H, Ogata H, Matsuoka K, Hisamatsu T, Watanabe M, Hibi T: Distinct colitogenic potential of Th17 and IL-17-producing LTi-like intestinal lymphocytes.
    Gastroenterology. 143:1288-1297, 2012.
    29 Yui S, Nakamura T, Sato T, Nemoto Y, Mizutani T, Zheng X, Ichinose S, Nagaishi T, Okamoto R, Tsuchiya K, Clevers H, Watanabe M: Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell.
    Nat Med. 18:618-623, 2012.
    30 Nemoto Y, Kanai T, Shinohara T, Ito T, Nakamura T, Okamoto R, Tsuchiya K, Lipp M, Eishi Y, Watanabe M: Luminal CD4+ T cells penetrate gut epithelial monolayers and egress from lamina propria to blood circulation.
    Gastroenterology. 141:2130-2139, 2011.
    31 Itsui Y, Sakamoto N, Kakinuma S, Nakagawa M, Sekine-Osajima Y, Tasaka-Fujita M, Nishimura-Sakurai Y, Suda G, Karakama Y, Mishima K, Yamamoto M, Watanabe T, Ueyama M, Funaoka Y, Azuma Cheng-Hsin and Watanabe M: Antiviral effects of the interferon-induced protein GBP-1 and its interaction with the hepatitis C virus NS5B protein.
    Hepatology. 50: 1727-1737, 2009.
    32 Tsuchiya K, Nakamura T, Okamoto R, Kanai T, Watanabe M: Reciprocal targeting of Hath1 and b-catenin by Wnt-glycogen synthase kinase 3b in human colon cancer.
    Gastroenterology. 132: 208-220, 2007.
    33 Nemoto Y, Kanai T, Makita S, Okamoto R, Totsuka T, Takeda K, Watanabe M: Bone marrow retaining colitogenic CD4+ T cells may be a pathogenic reservoir for chronic colitis.
    Gastroenterology. 132: 176-189, 2007.
    34 Matsumoto T, Okamoto R, Yajima T, Mori T, Okamoto S, Ikeda Y, Mukai M, Yamazaki M, Nakamura T, Kanai T, Hibi T, Inazawa J, Watanabe M: Increase of bone marrow-derived secretory lineage epithelial cells during regeneration in the human intestine.
    Gastroenterology. 128: 1851-1867, 2005.
    35 Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, Sakuraba A, Hitotsumatsu O, Fukushima T, Kanai T, Watanabe M, Ishii H, Hibi T: T-bet up-regulation and subsequent interleukin 12 stimulation are essential for the induction of Th1 mediated immunopathology in Crohn’s disease.
    Gut. 53: 1303-1308, 2004.
    36 Oshima S, Nakamura T, Namiki S, Okada E, Tsuchiya K, Okamoto R, Yamazaki M, Yokota T, Aida M, Yamaguchi Y, Kanai T, Handa H, Watanabe M: Interferon regulatory factor 1 (IRF-1) and IRF-2 distinctively up-regulate gene expression and production of interleukin-7 in human intestinal epithelial cells.
    Mol Cell Biol. 24: 6298-6310, 2004.
    37 Sato T, Kanai T, Watanabe M, Sakuraba A, Okamoto S, Nakai T, Okazawa A, Inoue N, Totsuka T, Yamazaki M, Kroczek RA, Fukushima T, Ishii H, Hibi T: Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease.
    Gastroenterology. 126: 829-839, 2004.
    38 Totsuka T, Kanai T, Iiyama R, Uraushihara K, Yamazaki M, Okamoto R, Hibi T, Tezuka K, Azuma M, Akiba H, Yagita H, Okumura K, Watanabe M: Ameliorating effect of anti-inducible co-stimulator monoclonal antibody in a murine model of chronic colitis.
    Gastroenterology. 124: 410-421, 2003.
    39 Sakamoto S, Yokota T, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Ye L, Kurosaki M, Taira K, Watanabe M, Mizusawa H: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived siRNAs.
    EMBO Rep. 4: 1-7, 2003.
    40 Okamoto R, Watanabe M: Prospects for regeneration of gastrointestinal epithelia using bone-marrow cells.
    Trends Mol Med. 9: 286-290, 2003.
    41 Ezaki T, Watanabe M, Inoue N, Kanai T, Ogata H, Iwao Y, Ishii H, Hibi T: A specific genetic alteration on chromosome 6 in ulcerative colitis-associated colorectal cancers.
    Cancer Res. 63: 3747-3749, 2003.
    42 Okamoto R, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, Ikeda Y, Hibi T, Inazawa J, Watanabe M: Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract.
    Nat Med. 8: 1011-1017, 2002.
    43 Chinzei R, Tanaka Y, Shimuzu-Saito K, Hara Y, Kakinuma S, Watanabe M, Teramoto K, Arii S, Takase K, Sato C, Terada N, Teraoka H: Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation into functional hepatocytes.
    Hepatology. 36: 22-29,2002.
    44 Inoue N, Watanabe M, Sato T, Okazawa A, Yamazaki M, Kanai T, Ogata H, Iwao Y, Ishii H, Hibi T: Restricted VH gene usage in lamina propria B cells that produced anticolon antibody from patients with ulcerative colitis.
    Gastroenterology. 121:15-23, 2001.
    45 Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M: Improvement in atrophic gastritis and intestinal metaplasia in patients from whom Helicobacter pylori was eradicated.
    Ann Int Med. 134: 380-386, 2001.
    46 Kanai T, Watanabe M, Nakamaru K, Okazawa A, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M, Hibi T: IL-18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn’s disease.
    Gastroenterology. 119: 1514-1523, 2000.
    47 Suzuki K, Oida T, Hamada H, Hitotsumatsu O, Watanabe M, Hibi T, Yamamoto H, Kubota E, Kaminogawa S, Ishikawa H: Gut cryptopatches: Direct evidence of extrathymic anatomical sites for intestinal T lymphopoiesis.
    Immunity. 13: 691-702, 2000.
    48 Nakazawa A, Watanabe M, Kanai T, Yajima T, Yamazaki M, Ogata H, Ishii H, Azuma M, Hibi T: Functional expression of a costimulatory molecule CD86 on epithelial cells in the inflamed colonic mucosa.
    Gastroenteology. 117: 536-545, 1999.
    49 Hisamatsu T, Watanabe M, Ogata H, Ezaki T, Kanai T, Hozawa S, Ishii H, Hibi T: IFN-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed colonic mucosa in ulcerative colitis.
    Cancer Res. 59: 5927-5931, 1999.
    50 Watanabe M, Ueno Y, Yajima T, Yamazaki M, Okamoto S, Hayashi T, Ishii H, Habu S, Uehira M, Nishimoto H, Hata J, Hibi T: Interleukin-7 transgenic mice develop chronic colitis with decrease of interleukin-7 protein accumulation in the colonic mucosa.
    J Exp Med. 187: 389-402, 1998.
    51 Watanabe M, Ueno Y, Yajima T, Iwao Y, Tuchiya M, Ishikawa H, Aiso S, Hibi T, Ishii H: Interleukin-7 is produced by human intestinalepithelial cells and regulates the proliferation of intestinal mucosal lymphocytes.
    J Clin Invest. 95: 2945-2953, 1995.
    52 Watanabe M, Boyson JE, Lord CI, Letvin NL: Chimpanzee immunized with recombinant soluble CD4 develop anti-self CD4 antibody responses with anti-human immunodeficiency virus activity.
    Proc Natl Acad Sci, USA. 89: 5103-5107, 1992.
    53 Watanabe M, Levine CG, Shen L, Fisher RA, Letvin NL: Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an anti-viral response.
    Proc Natl Acad Sci, USA. 88: 4616-4620, 1991.
    54 Watanabe M, Chen ZW, Tsubota H, Lord CI, Levine CG, Letvin NL: Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication.
    Proc Natl Acad Sci, USA. 88: 120-124, 1991.
    55 Watanabe M, Reimann KA, DeLong PA, Liu T, Fisher RA, Letvin NL: Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques.
    Nature. 337: 267-270, 1989.

2025年

  • 1 Mochida T, Miyoshi M, Kakinuma S, Shimizu T, Tsuchiya J, Watakabe K, Inada K, Kaneko S, Kawai-Kitahata F, Murakawa M, Nitta S, Nakagawa M, Watanabe M, Asahina Y, Okamoto R: Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids. Stem Cell Reports. doi: 10.1016/j.stemcr.2025.102642, 2025.
    2 Matsuoka K, Hirai F, Watanabe K, Hokari R, Kobayashi T, Saruta M, Nakase H, Suzuki T, Yamazaki G, Hibi T, Watanabe M, Hisamatsu T: Optimising Carotegrast Methyl Use in Ulcerative Colitis: Patient Profiling, Predictive Biomarkers, and Timing of Efficacy Evaluation （ASPECT Study）. J Gastroenterol. doi: 10.1007/s00535-025-02299-9, 2025.
    3 Nemoto Y, Morikawa R, Yonemoto Y, Tanaka S, Takei Y, Oshima S, Nagaishi T, Tsuchiya K, Nakamura T, Takenaka K, Ohtsuka K, Chen X, Okazawa H, Okamoto R, Watanabe M, von Andrian UH: Intestinal CD4-CD8αβ-TCRαβ+T cells function as tolerogenic antigen presenting cells in mice. Nat Commun. 16: 7072, 2025.
    4 Shimizu T, Miyoshi M, Kakinuma S, Tsuchiya J, Yamane D, Watakabe K. Mochida T, Inada K. Yamada K. Shinozaki K. Sato A, Kaneko S, Kawai-Kitahata F, Murakawa M, Nitta S, Nakagawa M, Watanabe M, Asahina Y, Okamoto R: Bile acid-FXR signaling facilitates the long-term maintenance of hepatic characteristics in human iPSC-derived organoids. Cell Reports. 44: 115675, 2025.
    5 Tsuchiya J, Miyoshi M, Kakinuma S, Kawai-Kitahata F, Kamiya A, Shimizu T, Sato A, Watakabe K, Mochida T, Inada K, Kamimae R, Kaneko S, Murakawa M, Nitta S, Nakagawa M, Watanabe M, Asahina Y, Okamoto R: HBV-KMT2B integration drives hepatic oncogenic processes in a human gene-edited iPSC-derived model.
    Cell Mol Gastroenterol Hepatol. 19: 101422, 2025.
    6 Hisamatsu D, Ikeba A, Yamato T, Mabuchi Y, Watanabe M, Akazawa C: Optimization of transplantation methods using isolated mesenchymal stem/stromal cells: clinical trials of inflammatory bowel diseases as an example. Inflamm Regen. 44: 37, 2024.
    7 Vieujean S, Schreiber S, Rubin DT, D’Haens G, Reinisch W, Watanabe M, Mehta R, Roblin X, Beales IL, Gietka P, Hibi T, Hospodarskyy I, Ritter T, Genovese MC, Kwon P, Santermans E, Le Brun FO, Barron R, Masior T, Denese S: Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn’s disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterology & Hepatology. 10:138-153, 2025.
    8 Takenaka K, Hisamatsu T, Kobayashi T, Yamamoto H, Ohmiya N, Hayashi R, Matsuoka K, Saruta M, Andoh A, Fukata N, Watanabe K, Imaeda H, Hirai F, Matsumoto T, Hirakawa A, Yano T, Matsuura M, Okamoto R, Ohtsuka K, Watanabe M: Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn’s Disease; A Prospective Multicenter Study. Clin Gastroenterol Hepatol. 23: 1991-2000 2025.

2024年

  • 1 Watakabe K, Miyoshi M, Kakinuma S, Sato A, Tsuchiya J, Shimizu T, Mochida T, Inada K, Kaneko S, Kawai-KitahataF, Murakawa M, Nitta S, Nakagawa M, Oshima, S, Watanabe M, Averil Ma, Asahina Y, Okamoto R: A20 in hepatic stellate cells suppresses chronic hepatitis by inhibiting DCLK1-JNK pathway-dependent chemokines. FASEB Journal. 38: e23757, 2024.
    2 Kobayashi T, Matsuoka K. Watanabe M, Hisamatsu T, Hirai F, Milata J, Li X, Morris N, Arora V, Ishizuka T, Matsuo K, Satoi Y, Milch C, Hibi T: Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies. Intest Res. 22: 172-185, 2024.
    3 Ogasawara N, Kano Y, Yoneyama Y, Kobayashi S, Watanabe S, Kirino S, Velez-Brabo FD, HongY, Ostapiuk A, Lutsik P, Onishi I, Yamauchi S, Hiraguri Y, Ito G, Kinugasa Y, Ohashi K, Watanabe M, Okamoto R, Tejpar S, Yui S: Discovery of Non-Genomic Drivers of YAP Signaling Modulating the Cell Plasticity in CRC Tumor Lines. iScience. 27: 109247, 2024.
    Vieujean S, Lindsay JO, D’Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK, Nagahori M, Watanabe M, Koutroubakis IE, Foteinogiannopoulou K, Avni Biron I, Walsh A, Outtier A, Nordestgaard RLM, Abreu MT, Dubinsky M, Siegel C, Louis E, Dotan I, Reinisch W, Danese S, Rubin DT, Peyrin-Biroulet L: Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases（IBD）：Real World Restults from the International Organization for the study of IBD. J Crohns Colitis. 18: 548-559, 2024.

2023年

  • 1 Takeuchi T, Nishikawa K, Yamada F, Morita A, Ohtsuki M, Suzuki Y, Watanabe M, Yamanaka H, HIbi T: Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseaes: Integrated Analysis of Three Japanese Prospective Observational Studies. Drug Saf. 46; 991-1005, 2023.
    2 Schreiber S, Rogler G, Watanabe M, Vermeire S, Maaser C, Danese S, Faes M, Hoek VP, Hsieh J, Moerch U, Zhou Y, Haas de A, Rudolph C, Oortwijn A, Loftus VE Jr: Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE. Aliment Pharmacol Ther. 58; 874-887, 2023.
    3 Matsuoka K, Yamazaki H, Nagahori M, Kobayashi T, Omori T, Mikami Y, Fujii T, Shinzaki S, Saruta M, Matsuura M, Yamamoto T, Motoya S, Hibi T, Watanabe M, Fernandez J, Fukuhara S, Hisamatsu T: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study. J Gastroenterol. 58: 751-765, 2023.
    4 Yamada D, Kojima Y, Hosoya A, Suzuki M, Watabe T, Inoue T, Tsugawa N, Asakawa T, Yonemoto Y, Onizawa M, Nemoto Y, Oshima S, Shimonaka M, Kuba K, Ishida J, Fukamizu A, Penninger JM, Watanabe M, Okamoto R, Nagaishi T: Apelin expression is downregulated in T cells in a murine model of chronic colitis. Biochem Biophys Res Commun. 647: 72-79, 2023.
    5 Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik LE, Pittet VEH, Annese V, Park KT, Katsanos KH., Høivik ML, Krznaric Z, Chaparro M, Loftus EV Jr, Lakatos PL, Gisbert JP, Bemelman W, Moum B, Gearry RB, Kappelman MD, Hart A, Pierik M, Andrews JM, Siew C. Ng SC, D’Inca R, Munkholm P: The Costs of Inflammatory Bowel Diseases in High-Income Settings. Lancet Gastroenterol Hepatol. 8: 458-492, 2023.
    6 Watanabe S, Ogasawara N, Kobayashi S, Kirino S, Inoue M, Hiraguri Y, Nagata S, Shimizu H, Ito G, Mizutani T, Nemoto Y, Tsuchiya K, Okamoto R, Watanabe M, Yui S: Organoids transplantation as a new modality to design epithelial signature to create a membrane-protective sulfomucin-enriched segment. J Gastroenterol. 58: 379-393, 2023.
    7 Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M: Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intest Res. 21: 110-125, 2023.
    8 Takenaka K, Kitazume Y, Kawamoto A, Fujii T, Udagawa Y, Watanabe R, Shimizu H, Hibiya S, Nagahori M, Ohtsuka K, Sato H, Hirakawa A, Watanabe M, Okamoto R: Serum Leucine-Rich 2 Glycoprotein: A Novel Biomarker For Transmural Inflammation in Crohn’s Disease. Am J Gastroenterol. 118: 1028-1035, 2023.
    9 Takenaka K, Kawamoto A, Kitazume Y, Fujii T, Udagawa Y, Shimizu H, Hibiya S, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R: Transmural remission characterized by high biologic concentrations demonstrates better prognosis in Crohn’s disease. J Crohns Colitis. 17: 855-862, 2023.
    10 Kitazume Y, Takenaka K, Ohtsuka K, Ozawa Y, Kimura K, Watanabe R, Tsuchiya J, Fujii T, Nagahori M, Watanabe M, Tateishi U: Motility Mapping Quantification Using the Classical Optical Flow Algorithm for Small Bowel Crohn’s Disease: Comparison with Balloon-assisted Enteroscopy Findings. Magn ResonMed Sci. 22: 325-334, 2023.
    11 Tamura A, Ito G, Matsuda H, Nibe-Shirakihara Y, Hiraoka Y, Kitagawa S, Hiraguri Y, Nagata S, Aonuma E, Otsubo K, Nemoto Y, Nagaishi T, Watanabe M, Okamoto R, Oshima S: Zranb1-mutant mice display abnormal colonic mucus production and exacerbation of DSS-induced colitis. Biochem Biophys Res Commun. 628: 147-154, 2023.

2022年

  • 1 Kobayashi S, Ogasawara N, Watanabe S, Yoneyama Y, Kiriono S, Hiraguri Y, Inoue M, Nagata S, Okamoto-Uchida Y, Kofuji S, Shimizu H, Ito G, Mizutani T, Yamauchi S, Kinugasa Y, Kano Y, Nemoto Y, Watanabe M, Tsuchiya K, Nishina H, Okamoto R, Yui S:
    Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammation.
    Inflamm Regen. 28: 49, 2022.
    2 Takahashi J, Mizutani T, Sugihara HY, Nagata S, Kato S, Hiraguri Y, Takeoka S, Tsuchiya M, Kuno R, Kakinuma S, Watanabe M, Okamoto R:
    Suspension culture in a rotating bioreactor for efficient generation of human intestinal organoids.
    Cell Rep Methods. 15: 100337, 2022.
    3 Hibiya S, Ohtsuka K, Takenaka K, Kawamoto A, Matsuyama Y, Udagawa Y, Motobayashi M, Shimizu H, Fujii T, Saito E, Nagahori M, Okamoto R, Watanabe M:
    Mucosal healing of small intestinal stricture is associated with improved prognosis post-dilation in Crohn’s disease.
    BMC Gastroenterol. 22: 218, 2022.
    4 Panes J, Colombel JF, D’Hanes GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebve J, Finney-Hayward T, Gonzalez YS, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ:
    Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
    Gastroenterology. 162: 1891–1910, 2022.
    5 Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T:
    AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled phase 3 study.
    Lancet Gastroenterol Hepatol. 7: 648–657, 2022.
    6 Matsuda H, Nibe-Shirakihara Y, Tamura A, Aonuma E, Arakawa S, Otsubo K, Nemoto Y, Nagaishi T, Tsuchiya K, Shimizu S, Ma A, Watanabe M, Uo M, Okamoto R, Oshima S:
    Nickel particles are present in Crohn’s disease tissue and exacerbate intestinal inflammation in IBD susceptible mice.
    Biochem Biophys Res Commun. 592: 74–80, 2022.
    7 Watanabe S, Kobayashi S, Ogasawara N, Okamoto R, Nakamura T, Watanabe M, Kim BJ, Yui S:
    Transplantation of intestinal organoids into a mouse model of colitis.
    Nat Protoc. 17: 649–671, 2022.
    8 Takenaka K, Kawamoto A, Okamoto R, Watanabe M, Ohtsuka K:
    Artificial intelligence for endoscopy in inflammatory bowel disease.
    Intest Res. 20: 165–170, 2022.
    9 Takenaka K, Fujii T, Kawamoto A, Suzuki K, Shimizu H, Maeyashiki C, Yamaji O, Motobayashi M, Igarashi A, Hanazawa R, Hibiya S, Nagahori M, Saito E, Okamoto R, Ohtsuka K, Watanabe M:
    Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol. 7: 230–237, 2022.
    10 Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T:
    Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.
    J Gastroenterol Hepatol. 37: 81–88, 2022.
    11 Nagaishi T, Watabe T, Kotake K, Kumazawa T, Aida T, Tanaka K, Ono R, Ishino F, Usami T, Miura T, Hirakata S, Kawasaki H, Shinkura R, Tsugawa N, Yamada D, Hirayama K, Yoshikawa S, Karasuyama H, Okamoto R, Watanabe M, Blumberg RS, Adachi T:
    Immunoglobulin A-specific deficiency induces spontaneous inflammation specifically in the ileum.
    Gut. 71: 487–496, 2022.
    12 Yasutomi Y, Chiba A, Haga K, Murayama G, Makiyama A, Kuga T, Watanabe M, Okamoto R, Nagahara A, Nagaishi T, Miyake S:
    Activated Mucosal-associated Invariant T Cells Have a Pathogenic Role in a Murine Model of Inflammatory Bowel Disease.
    Cell Mol Gastroenterol Hepatol. 13: 81–93, 2022.
    13 Watanabe S, Hibiya S, Katsukura N, Kitagawa S, Sato A, Okamoto R, Watanabe M, Tsuchiya K:
    Importance of telomere shortening in the pathogenesis of ulcerative colitis: a new treatment from the aspect of telomeres in intestinal epithelial cell.
    J Crohns Colitis. 16: 109–121, 2022.
    14 Ando K, Fujiya M, Hiraoka S, Shiga H, Tanaka S, Iijima H, Mizushima T, Kobayashi T, Kawamoto A, Takenaka K, Hibiya S, Ohtsuka K, Okamoto R, Watanabe M:
    Serum leucine-rich α-2 glycoprotein; a novel biomarker for small bowel mucosal activity in Crohn’s Disease.
    Clin Gastroenterol Hepatol. 20: e1196–e1200, 2022.

2021年

  • 1 Nagahori M, Ikeuchi H, Kato S, Torisu T, Kobayashi K, Higashiyama M, Fukui T, Kogaya T, Esaki M, Yanai S, Abukawa D, Naganuma M, Motoya S, Saruta M, Bamba S, Sasaki M, Uchiyama K, Fukuda K, Suzuki H, Nakase H, Shimizu T, Iizuka M, Watanabe M, Suzuki Y, Hisamatsu T: A nationwide survey concerning the mortality and risk of progressing severity dur to arterial and venous thromboembolism in inflammatory bowel disease in Japan. J Gastroenterol. 56: 1062-1079, 2021.
    2 D’Haens G, Danese S, Davies M, Watanabe M, Hibi T: A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn’s Disease. J Crohns Colitis. 16: 746-756, 2021.
    3 Takenaka K, Kawamoto A, Hibiya S, Suzuki K, Fujii T, Motobayashi M, Shimizu H, Nagahori M, Saito E, Okamoto R, Watanabe M, Ohtsuka K: Higher concentrations of cytokine blockers are needed to obtain small bosel mucosal healing during maintenance therapy in Crohn’s disease. Aliment Pharmacol Ther. 54: 1052-1060, 2021.
    4 Minamidate A, Onizawa M, Saito C, Hikichi R, Mochimaru T, Murakami M, Sakuma C, Asakawa T, Hiraoka Y, Oshima S, Nagaishi T, Tsuchiya K, Ohira H, Okamoto R, Watanabe M: A potent endocytosis inhibitor Ikarugamycin up-regulates TNF production. Biochem Biophys Res. doi: 10.1016/j.bbrep.2021.101065., 2021.
    5 Shimizu H, Fujii T, Kinoshita K, Kawamoto A, Hibiya S, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R: Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol. 21: 494, 2021.
    6 Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T: Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenteol. 56: 560-569, 2021.
    7 Asakawa T, Onizawa M, Saito C, Hikichi R, Yamada D, Minamidate A, Mochimaru T, Asahara SI, Kido Y, Oshima S, Nagaishi T, Tsuchiya K, Ohira H, Okamoto R, Watanabe M: Oral administration of D-serine prevents the onset and progression of colitis in mice. J Gastroenterol. 56: 732-745, 2021.
    8 Watanabe S, Hibiya S, Katsukura N, Kitagawa S, Sato A, Okamoto R, Watanabe M, Tsuchiya K: Influence of chronic inflammation on the malignant phenotypes and the plasticity of colorectal cancer cells. Biochem Biophys Rep. doi: 10.1016/j.bbrep.2021.101031., 2021.
    9 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fujii T, Watanabe K, Nakamura S, Inoue N, Itoh T, Maganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K: Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 56: 489-526, 2021.
    10 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group: Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA)： a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 6: 429-437, 2021.
    11 Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L: Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 397: 2372-2384, 2021.
    12 Kaneshiro M, Takenaka K, Suzuki K, Fujii T, Hibiya S, Kawamoto A, Motobayashi M, Shimizu H, Nagahori M, Saito E, Okamoto R, Ohtsuka K, Watanabe M: Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission. Aliment Pharmacol Ther. 53: 900-907, 2021.
    13 Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J: Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 36: 637-645, 2021.
    14 Watanabe S, Nishimura R, Shirasaki T, Katsukura N, Hibiya S, Kirimura S, Negi M, Okamoto R, Matsumoto Y, Nakamura T, Watanabe M, Tsuchiya K: Schlafen 11 is a novel target for mucosal regeneration in Ulcerative Colitis. J Crohns Colitis. 25: 1558-1572, 2021.
    15 Morikawa R, Nemoto Y, Yonemoto Y, Tanaka S, Takei Y, Oshima S, Nagaishi T, Tsuchiya K, Nozaki K, Mizutani T, Nakamura T, Watanabe M, Okamoto R: Intraepithelial lymphocytes suppress the intestinal tumor growth by cell-to-cell contact via CD103/E-cadherin signal. Cell Mol Gastroenterol Hepatol. 11: 1483-1503, 2021.
    16 Kuno R, Ito G, Kawamoto A, Hiraguri Y, Sugihara HY, Takeoka S, Nagata S, Takahashi J, Tsuchiya M, Anzai S, Mizutani T, Shimizu H, Yui S, Oshima S, Tsuchiya K, Watanabe M, Okamoto R: Notch and TNF-a signaling promote cytoplasmic accumulation of OLFM4 in intestinal epithelium cells and exhibit a cell protective role in the inflamed mucosa of IBD patients. Biochem Biophys Res Commun. doi: 10.1016/j.bbrep.2020.100906., 2021.
    17 Takenaka K, Ohtsuka K, Fujii T, Oshima S, Okamoto R, Watanabe M: Deep neural network accurately predicts prognosis of ulcerative colitis using endoscopic images. Gastroenterology. 160: 2175-2177, 2021.
    18 Aonuma E, Tamura A, Matsuda H, Asakawa T, Sakamaki Y, Otsubo K, Nibe Y, Onizawa M, Nemoto Y, Nagaishi T, Tsuchiya K, Nakamura T, Uo M, Watanabe M, Okamoto R, Oshima S: Nickel ions attenuate autophagy flux and induce transglutaminase 2 (TG2) mediated post-translational modification of SQSTM1/p62. Biochem Biophys Res Commun. 542: 17-23, 2021.
    19 Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M: Intestinal cancer in patients with Crohn’s disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 36: 329-336, 2021.
    20 Tsuchiya M, Ito G, Hama M, Nagata S, Kawamoto A, Suzuki K, Shimizu H, Anzai S, Takahashi J, Kuno R, Takeoka S, Hiraguri Y, Sugihara HY, Mizutani T, Yui S, Oshima S, Tsuchiya K, Watanabe M, Okamoto R: Functional analysis of isoflavones using patient-derived human colonic organoids. Biochem Biophys Res Commun. 542: 40-47, 2021.
    21 Tsugawa N, Yamada D, Watabe T, Onizawa M, Wang S, Oshima S, Tsubata T, Adachi T, Kawano Y, Watanabe M, Blumberg RS, Okamoto R, Nagaishi T: CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. Biochem Biophys Res Commun. 535: 99-105, 2021.
    22 Hibiya S, Matsuyama Y, Fujii T, Maeyashiki C, Saito E, Ito K, Shimizu H, Kawamoto A, Motobayashi M, Takenaka K, Nagahori M, Kurosaki M, Yauchi T, Ohtsuka K, Fujiwara T, Okamoto R, Watanabe M: 5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis. Aliment Pharmacol Ther. 53: 103-113, 2021.
    23 Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M: Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn’s disease? Systematic review and meta-analysis. J Gastroenterol Hepatol. 36: 864-872, 2021.
    24 Higashiyama M, Komoto S, Suzuki Y, Watanabe M, Hibi T, Miura S, Hokari R: Relation of geriatric nutritional risk index with clinical risks in elderly-onset ulcerative colitis. J Gastroenterol Hepatol. 36: 163-170, 2021.
    25 Kato S, Shimizu H, Tomii S, Uchida H, Kawamoto A, Hibiya S, Motobayashi M, Takenaka K, Fujii T, Saito E, Nagahori M, Ohtsuka K, Negi M, Akashi T, Matsuyama T, Kinugasa Y, Watanabe M: Substantial Epstein-Barr virus reactivation in a case of severe refractory ulcerative colitis: a possible role in exacerbation. Clin J Gastroenterol. 14: 584-588, 2021.
    26 Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M: Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn’s disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 36: 1744-1753, 2021.
    27 Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T: Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol. 36: 2091-2100, 2021.
    28 Nagahori M, Watanabe K, Motoya S, Ogata H, Kanai T, Suzuki Y, Pinton P, Ursos L, Sakamaoto S, Shikamura M, Hori T, Fernandez J, Hibi T, Watanabe M: Week 2 Symptomatic Response with Vedolizmab as a Predictive Factor in Japanese Anti-TNF-a-Naïve Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Digestion. 15: 1-11, 2021.
    29 Shimizu H, Fujii T, Motobayashi M, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M: Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intest Res. 19:115-118, 2021.
    30 Katsukura N, Watanabe S, Shirasaki T, Hibiya S, Kano Y, Akahoshi K, Tanabe M, Kirimura S, Akashi T, Kitagawa M, Okamoto R, Watanabe M, Tsuchiya K: Intestinal phenotype is maintained by Atoh1 in the cancer region of intraductal papillary mucinous neoplasm. Cancer Sci. 112: 932-944, 2021.

2020年

  • 1 Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H, Matsui T, Watanabe M, Hibi T: Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study. Intest Res. doi: 10.5217/ir.2020.00025., 2020.
    2 Kitazume Y, Tsuchiya J, Takenaka K, Ohtsuka K, Kimura K, Watanabe R, Fujioka T, Fujii T, Watanabe M, Tateisi U: High b-value computed diffusion-weighted imaging for differentiating bowel inflammation in Crohn’s disease. Eur J Radiol. doi: 10.1111/jgh.15288., 2020.
    3 Tsuda S, Sameshima A, Sekine M, Kawaguchi H, Fujita D, Makino S, Morinobu A, Murakawa Y, Matsui K, Sugiyama T, Watanabe M, Suzuki Y, Nagahori M, Murashima A, Atsumi T, Oku K, Mitsuda M, Takei S, Miyamae T, Takahashi N, Nakajima K, Saito S; Ministry of Health Labour and Welfare Working Group for “Guideline for The Treatment of Rheumatoid Arthritis or Inflammatory Bowel Disease Bearing Women in Child-bearing Age”.: Pre-conception status, obstetric outcome and use of medications during pregnancy of SLE, RA and IBD in Japan: Multi-center retrospective descriptive study. Mod Rheumatol. 30: 852-861, 2020.
    4 Nakagawa M, Nawa N, Takeichi E, Shimuzu T, Tsuchiya J, Sato A, Miyoshi M, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Fujiwara T, Watanabe M, Tanaka Y, Asahina Y; Ochanomizu Liver Conference Study Group.: Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol. 55: 990-999, 2020.
    5 Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T: Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Intest Res. doi: 10.5217/ir.2020.00026., 2020.
    6 Hata K, Ishihara S, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Kunisaki R, Nakase H, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Shinozaki M, Ogata N, Moriichi K, Hirai F, Sugihara K, Hisamatsu T, Suzuki Y, Watanabe M, Hibi T: Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. J Clin Med. 9: 2286, doi: 10.3390/jcm9072286., 2020.
    7 Iijima H, Kobayashi T, Nagasaka M, Shinzaki S, Kitamura K, Suzuki Y, Watanabe M, Hibi T: Management of primary nonresponders and partial responders to TNF-α inhibitor induction therapy among patients with Crohn’s disease. Inflamm Intest Dis. 5: 78-83, 2020.
    8 Takenaka K, Fujii T, Suzuki K, Shimizu H, Motobayashi M, Hibiya S, Saito E, Nagahori M, Watanabe M, Ohtsuka K: Small bowel healing detected by endoscopy in patients with Crohn’s disease after treatment with antibodies against TNF. Clin Gastroenterol Hepatol. 18: 1545-1552, 2020.
    9 Takenaka K, Kitazume Y, Fujii T, Tsuchiya K, Watanabe M, Ohtsuka K: Objective evaluation for treat-to-target in Crohn’s disease. J Gastroenterol. 55: 579-587, 2020.
    10 Takenaka K, Ohtsuka K, Fujii T, Negi M, Suzuki K, Shimizu H, Oshima S, Akiyama S, Motobayashi M, Nagahori M, Saito E, Matsuoka K, Watanabe M: Development and validation of a deep neural network for accurate evaluation of endoscopic images from patients with ulcerative colitis. Gastroenterology. 158: 2150-2157, 2020.
    11 Anzai S, Kawamoto A, Nagata S, Takahashi J, Kawai M, Kuno R, Kobayashi S, Watanabe S, Suzuki K, Shimizu H, Hiraguri Y, Takeoka S, Sugihara HY, Yui S, Oshima S, Watanabe M, Okamoto R: TGF-β promotes fetal gene expression and cell migration velocity in a wound repair model of untransformed intestinal epithelial cells. Biochem Biophys Res Commun. 524: 533-541, 2020.
    12 Saruta M, Park DI, Kim YH, Yang SK, Jang BI, Cheon JH, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick KJ, Cataldi F, Watanabe M, Hibi T: Anti-MAdCAM-1 antibody (PF-00548659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study. Intest Res. 18: 45-55, 2020.
    13 Otsubo K, Maeyashiki C, Nibe Y, Tamura A, Aonuma E, Matsuda H, Kobayashi M, Onizawa M, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Torii S, Itakura E, Watanabe M, Oshima S: Receptor-interacting protein kinase 3 (RIPK3) inhibits autophagic flux during necroptosis in intestinal epithelial cells. FEBS Lett. 594: 1586-1595, 2020.
    14 Okamoto R, Shimizu H, Suzuki K, Kawamoto A, Takahashi J, Kawai M, Nagata S, Hiraguri Y, Takeoka S, Sugihara HY, Yui S, Watanabe M: Organoid-based regenerative medicine for inflammatory bowel disease. Regen Ther. 13: 1-6, 2020.
    15 Takei Y, Nemoto Y, Morikawa R, Tanaka S, Oshima S, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Watanabe M: CD8αα+ T cells show amoeboid shape and frequent morphological change in vitro, and localize to small intestinal intraepithelial region in vivo. Biochem Biophys Res Commun. 523: 328-335, 2020.
    16 Hibi T, Naganuma M, Oda E, Yamada Y, Chujoh Y, Yoshihara R, Watanabe M: Predictive factor for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of two clinical trials. Intest Res. 18: 56-68, 2020.
    17 Tanaka S, Nemoto Y, Takei Y, Morikawa R, Oshima S, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Stutte S, Watanabe M: High-fat diet–derived free fatty acids impair the intestinal immune system and increase sensitivity to intestinal epithelial damage. Biochem Biophys Res Commun. 522: 971-977, 2020.
    18 Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Kenkichi S, Oda K, Hori T, Araki T, Watanabe M, Hibi T: Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. J Gastroenterol. 55: 291-306, 2020.
    19 Nitta S, Takahashi K, Kawai-Kitahata F, Tsuchiya J, Sato A, Miyoshi M, Murakawa M, Istui Y, Nakagawa M, Azuma S, Kakinuma S, Watanabe M, Asahina Y: Time course alterations of virus sequences and immunoglobulin titers in a chronic hepatitis E patient. Hepatol Res. 50: 524-531, 2020.

2019年

  • 1 Sato A, Kakinuma S, Miyoshi M, Kamiya A, Tsunoda T, Kaneko S, Tsuchiya J, Shimizu T, Takeichi E, Nitta S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Koshikawa N, Seiki M, Nakauchi H, Asahina Y, Watanabe M: Vasoactive Intestinal Peptide Derived from Liver Mesenchymal Cells Mediates Tight Junction Assembly in Mouse Intrahepatic Bile Ducts. Hepatol Commun. 4: 235-254, 2019.
    2 Suzuki Y, Watanabe M, Matsui T, Motoya S, Hisamatsu T, Yuasa H, Tabira J, Isogawa N, Tsuchiwata S, Arai S, Hibi T: Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitits. Inflamm Intest Dis. 4: 131-143, 2019.
    3 Yamazaki H, Matsuoka K, Fernandez J, Hibi T, Watanabe M, Hisamatsu T, Fukuhara S: Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS（YOu and Ulcerative colitis: Registy and Social network）. BMJ Open. 9(9): e030134. doi: 10.1136/bmjopen-2019-030134., 2019.
    4 Kakinuma S, Watanabe M: Analysis of the mechanism underlying liver diseases using human induced pluripotent stem cells. Immunol Med. 42: 71-78, 2019.
    5 Nakagawa T, Kobayashi T, Nishikawa K, Yamada F, Asai S, Sameshima Y, Suzuki Y, Watanabe M, HIbi T: Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 17: 504-515, 2019.
    6 Naganuma M, Hirai F, Kobayashi K, Watanabe K, Takeuchi K, Aoyoama N, Nozawa H, Motoya S, Ohmori T, Harada A, Nagai Y, Abe T, Yamada Y Inagaki K, Shimizu N, Kanai T, Watanabe M; ESCORT study Group.: Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonoide rectal foam. PLoS One. 14(8): e0220413. doi: 10.1371/journal.pone.0220413, 2019.
    7 Kawai-Kitahata F, Asahina Y, Kaneko S, Tsuchiya J, Sato A, Miyoshi M, Tsunoda T, Inoue-Shinomiya E, Murakawa M, Nitta S, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Tanabe M, Sugawara E, Takemoto A, Ojima H, Sakamoto M, Muraoka M, Takano S, Maekawa S, Enomoto N, Watanabe M: Comprehensive genetic analysis of cholangiolocellular carcinoma with a co-existent hepatocellular carcinoma (HCC)-like area and metachronous HCC. Hepatol Res. 49: 1466-1474, 2019.
    8 Akiyama S, Matsuoka K, Fukuda K, Hamada S, Shimizu M, NankiK, Mizuno S, Kiyohara H, Arai M, Sugimoto S, Iwao Y, Ogata H, Hisamatsu T, Naganuma M, Motobayashi M, Suzuki K, Takenaka K, Fujii T, Saito E, Nagahori M, Ohtsuka K, Mochizuki M, Watanabe M, Hashiguchi M, Kanai T: Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine. J Gastroenterol Hepatol. 34: 1751-1757, 2019.
    9 Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Wtanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Mtasumoto T; DIAMOND2 Study Group.: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomized clinical trial (DIAMOND2). J Gastroenterol. 54: 860-870, 2019.
    10 Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N: Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 34: 2004-2010, 2019.
    11 Watanabe S, Tsuchiya K, Nishimura R, Shirasaki T, Katsukura N, Hibiya S, Okamoto R, Nakamura T, Watanabe M: TP53 mutation by CRISPR system enhances the malignant potential of colon cancer. Mol Cancer Res. 17: 1459-1467, 2019.
    12 Nagaishi T, Yamada D, Suzuki K, Fukuyo R, Saito E, Fukuda M, Watabe T, Tsugawa N, Takeuchi K, Yamamoto K, Arai A, Ohtsuka K, Watanabe M: Indolent T cell lymphoproliferative disorder with villous atrophy in small intestine diagnosed by single-balloon enteroscopy. Clin J Gastroenterol. 12: 434-440, 2019.
    13 Nitta S, Asahina Y, Kato T, Tsuchiya J, Inoue-Shinomiya E, Sato A, Tsunoda T, Miyoshi M, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Hikita H, Takehara T, Watanabe M: Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. Sci Rep. 9: 5722. doi: 10.1038/s41598-019-42114-z, 2019.
    14 Tsunoda T, Kakinuma S, Miyoshi M, Kamiya A, Kaneko S, Sato A, Tsuchiya J, Nitta S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Sogo T, Komatsu H, Mukouchi R, Inui A, Fujisawa T, Nakauchi H, Asahina Y, Watanabe M: Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium. J Hepatol. 71: 143-152, 2019.
    15 Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PloS One. 14: e0212989, 2019.
    16 Miyoshi M, Kakinuma S, Kamiya A, Tsunoda T, Tsuchiya J, Sato A, Kaneko S, Nitta S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Nakauchi H, Asahina Y, Watanabe M: LIM homeobox 2 promotes interaction between human iPS-derived hepatic progenitors and iPS-derived hepatic stellate-like cells. Sci Rep. 9: 2072. doi: 10.1038/s41598-018-37430-9, 2019.
    17 Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group.: Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn’s disease: a sub-analysis of a prospective randomized clinical trial（DIAMOND study）. J Crohns Colitis. 13: 1097-1104, 2019.
    18 Azuma S, Asahina Y, Kakinuma S, Azuma K, Miyoshi M, Inoue E, Tsunoda T, Sato A, Kaneko S, Nagata H, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Tomita M, Nakagawa M, Watanabe M: Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Dig. Dis. 37: 247-254, 2019.
    19 Inoue-Shinomiya E, Murakawa M, Asahina Y, Nakagawa M, Tsuchiya J, Sato A, Tsunoda T, MiyoshiM, Nitta S, Kawai-Kitahata F, Itsui Y, Azuma S, Kakinuma S, Murata K, Mizokami M, Watanabe M: The association of serum IFN-λ3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. Hepatol Res. 49: 500-511, 2019.
    20 Nishimura R, Shirasakai T, Tsuchiya K, Miyake Y, Watanabe Y, Hibiya S, Watanabe S, Nakamura T, Watanabe M: Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids. J Gastroenterol. 54: 608-620, 2019.
    21 Motobayashi M, Matsuoka K, Takenaka K, Fujii T, Nagahori M, Ohtsuka K, Iwamoto F, Tsuchiya K, Negi M, Eishi Y, Watanabe M: Predictors of mucosal healing during induction therapy in patients with acute moderate-to-severe ulcerative colitis. J Gastroenterol Hepatol. 34: 1004-1010, 2019.
    22 Esaki M, Matsumoto T, Ohmiya N, Washio E, Morishita T, Sakamoto K, Abe H, Yamamoto Kawamoto A, Nagata S, Anzai S, Takahashi J, Kawai M, Hama M, Nogawa D, Yamamoto K, Kuno R, Suzuki K, Shimizu H, Hiraguri Y, Yui S, Ohshima S, Tsuchiya K, Nakamura T, Ohtsuka K, Kitagawa M, Okamoto R, Watanabe M: Ubiquitin D is up-regulated by synergy of Notch signalling and TNF-α in the inflamed intestinal epithelia of IBD patients. J Crohns Colitis. 13: 495-509, 2019.
    23 S, Kinjo T, Togashi K, Watanabe K, Hirai F, Nakamura M, Nouda S, Ashizuka S, Omori T, Kochi S, Yanai S, Fuyuno Y, Hirano A, Umeno J, Kitazono T, Kinjo F, Watanabe M, Matsui T, Suzuki Y: Capsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case-control study. J Gastroenterol. 54: 249-260, 2019.
    24 Shimizu H, Suzuki K, Watanabe M, Okamoto R: Stem cell-based thrapy for inflammatory bowel disease. Intest Res. 17: 311-316, 2019.

2018年

  • 1 Oshima S, Watanabe M: Genetic and environmental factors drive personalized medicine for Crohn’s disease. J Clin Invest. 128: 4758-4760, 2018.
    2 Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson A, Singh R, Mostafa N, Suzuki Y, Hibi T: Efficacy and safety of dose escalation to adalimumab 80 mg every other week in Japanese patients with Crohn’s disease who lost response to maintenance therapy. Inflamm Bowel Dis. 2: 228-235, 2018.
    3 Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group.: Effect of elemental diet combined with infliximab dose escalation in patients with Crohn’s disease with loss of response to infliximab: CERISIER trial. Intest Res. 16: 494-498, 2018.
    4 Iwamoto F, Matsuoka K, Motobayashi M, Takenaka K, Kuno T, Tanaka K, Tsukui Y, Kobayashi S, Yoshida T, Fujii T, Saito E, Yamaguchi T, Nagahori M, Sato T, Ohtsuka K, Enomoto N, Watanabe M: Fecal calprotectin predicts disease activity of Crohn’s disease evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol. 33: 1984-1989, 2018.
    5 Hosoe N, Nakano M, Takeuchi K, Endo Y, Matsuoka K, Abe T, Omori T, Hayashida M, Kobayashi T, Yoshida A, Mizuno S, Yoshihiro N, Naganuma M, Kanai T, Watanabe M, Ueno F, Suzuki Y, Hibi T, Ogata H: Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis-Capsule Scoring of Ulcerative Colitis. Inflamm Bowel Dis. 24: 2641-2647, 2018.
    6 Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest. Res. 16: 233-245, 2018.
    7 Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T: Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intest Res. 16: 168-177, 2018.
    8 Weng MT, Park SH, Matsuoka K, Tung CC, Lee JY, Chang CH, Yang SK, Watanabe M, Wong JM, Wei SC: Incidence and risk factor analysis of thromboembolic events in east asian patients with inflammatory bowel disease, a multinational collaborative study. Inflamm Bowel Dis. 24: 1791-1800, 2018.
    9 Calabrese E, Kucharzik T, Maaser C, Maconi G, Strobel D, Wilson SR, Zorzi F, Novak KL, Bruining DH, Iacucci M, Watanabe M, Lolli E, Chiaramonte C, Hanauer SB, Panaccione R, Pallone F, Ghosh S, Monteleone G: Real-time interobserver agreement in bowel ultrasonography for diagnostic assessment in patients with Crohn’s disease: An international multicenter study. Inflamm Bowel Dis. 24: 2001-2006, 2018.
    10 Komoto S, Higashiyama M, Watanabe C, Suzuki Y, Watanabe M, Hibi T, Takebayashi T, Asakura K, Nishiwaki Y, Miura S, Hokari R: Clinical differences between elderly-onset and non-elderly-onset ulcerative colitis: A nationwide survey data in Japan. J Gastroenterol Hepatol. 33: 1839-1843, 2018.
    11 Wada Y, Fukuda M, Ohtsuka K, Watanabe M, Fukuma Y, Wada Y, Wada M: Efficacy of Endocuff-assisted colonoscopy in the detection of colorectal polyps. Endosc Int Open. 6: E425-E431, 2018.
    12 Akiyama S, Nagahori M, Oooka S, Negi M, Ito T, Takenaka K, Ohtsuka K, Watanabe M: Small intestinal obstruction due to the metastasis of intrahepatic cholangiocarcinoma: A case report. Medicine (Baltimore). 97: e0190. doi: 10.1097/MD.0000000000010190. 2018.
    13 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T: Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 53: 305-353, 2018.
    14 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK: Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res. 16: 4-16, 2018.
    15 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK: Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Park 1: risk assessment. Intest Res. 16: 17-25, 2018.
    16 Fukushima K, Sugita A, Futami K, Takahashi KI, Motoya S, Kimura H, Yoshikawa S, Kinouchi Y, Iijima H, Endo K, Hibi T, Watanabe M, Sasaki I, Suzuki Y; Surgical Research Group, the Research Committee of Inflammatory Bowel Disease, the Ministry of Health, Welfare and Labor of Japan: Postoperative therapy with infliximab for Crohn’s disease: a 2-year prospective randomized multicenter study in Japan. Surg Today. 48: 584-590, 2018.
    17 Suzuki K, Murano T, Shimizu M, Ito G, Nakata T, Fujii S, Ishibashi F, Kawamoto A, Anzai S, Kuno R, Kuwabara K, Takahashi J, Hama M, Nagata S, Hiraguri Y, Takenaka K, Yui S, Tsuchiya K, Nakamura T, Ohtsuka K, Watanabe M, Okamoto R: Single cell analysis of Crohn’s disease patient-derived small intestinal organoids reveals disease activity-dependent modification of stem cell properties. J Gastroenterol. 53: 1035-1047, 2018.
    18 Watabe T, Nagaishi T, Tsugawa M, Kojima Y, Jose N, Hosoya A, Onizawa M, Nemoto Y, Oshima S, Nakamura T, Karasuyama H, Adachi T, Watanabe M: B cell activation in the cecal patches during the development of an experimental colitis model. Biochem Biophys Res Commun. 496: 367-373, 2018.
    19 Naganuma M, Aoyama N, Tada T, Kobayashi K, Hirai F, Watanabe K, Watanabe M, Hibi T: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol. 53: 494-506, 2018.
    20 Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Nagahori M, Fujii T, Saito E, Kimura M, Fujioka T, Watanabe M: Utility of magnetic resonance enterography for small bowel endoscopic healing in patients with Crohn’s disease. Am J Gastroenterol. 113: 283-294, 2018.
    21 Yui S, Azzolin L, Maimets M, Pedersen M, Fordham R, Hansen S, Guiu J, Alves M, Rundsen C, Johansen J, Li Y, Madsen C, Nakamura T, Wanatabe M, Nielsen O, Schweiger P, Piccolo S, Jensen K: YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell. 22: 35-49, 2018.
    22 Ishibashi F, Shimizu H, Nakata T, Fujii S, Suzuki K, Kawamoto A, Anzai S, Kuno R, Nagata S, Ito G, Murano T, Mizutani T, Oshima S, Tsuchiya K, Nakamura T, Watanabe M, Okamoto R: Contribution of ATOH1+ cells to the homeostasis, repair and tumorigenesis of the colonic epithelium. Stem Cell Rep. 10: 27-42, 2018.
    23 Hirai F, Andoh A, Ueno F, Watanabe K, Ohmiya N, Nakase H, Kato S, Esaki M, Endo Y, Yamamoto H, Matsui T, Iida M, Hibi T, Watanabe M, Suzuki Y, Matsumoto T: Efficacy of endoscopic balloon dilation for small bowel strictures in patients with Crohn’s disease: A nationwide, multi-center, open-label, prospective cohort study. J Crohns Colitis. 12: 394-401, 2018.
    24 Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S, Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T; INDIGO Study Group: Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis. Gastroenterology. 154: 935-947, 2018.
    25 Nibe Y, Oshima S, Kobayashi M, Maeyashiki C, Matsuzawa Y, Otsubo K, Matsuda H, Aonuma E, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Nakada S, Watanabe M: Novel polyubiquitin imaging system, PolyUb-FC, reveals that K33-linked polyubiquitin is recruited by p62/SQSTM1. Autophagy. 24: 347-358, 2018.
    26 Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group: Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease. Clin. Gastroenterol. Hepatol. 16: 542-549, 2018.
    27 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK: Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. J Gastroenterol Hepatol. 33: 30-36, 2018.
    28 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK: Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Park 1: risk assessment. J Gastroenterol Hepatol. 33: 20-29, 2018.

2017年

  • 1 Akiyama S, Mochizuki W, Nibe Y, Matsumoto Y, Sakamoto K, Oshima S, Watanabe M, Nakamura T: CCN3 expresssion marks a sulfomucin-nonproducing unique subset of colonic goblet cells in mice. Acta histochem Cytochem. 50: 159-168, 2017.
    2 An J, Nagaishi T, Watabe T, K. Naruse T, Watanabe M, Kimura A: MKL1 expressed in macrophages contributes to the development of murine colitis. Sci. Rep. 7(1):13650. doi: 10.1038/s41598-017-13629-0, 2017.
    3 Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, YoshimuraN, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T: Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 46:873-882, 2017.
    4 Matsumoto Y, Mochizuki W, Akiyama S, Matsumoto T, Nozaki K, Watanabe M, Nakamura T: Distinct intestinal adaptation for vitamin B12 and bile acid absorption revealed in a new mouse model of massive ileocecal resection. Biol Open. 15: 1364-1374, 2017.
    5 Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Nouchi T, Sakai H, Tomita M, Watanabe M, and the Ochanomizu Liver Conference Study Group: Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatology 67: 933-939, 2017.
    6 Hibiya S, Tsuchiya K, Hayashi R, Horita N, Watanabe S, Shirasaki T, Nishimura R, Kimura N, Nishimura T, Gotoh N, Oshima S, Okamoto R, Nakamura T, Watanabe M: Long-term inflammation transforms intestinal epithelial cells of colonic organoids. J Crohns Colitis. 11: 621-630, 2017.
    7 Akiyama S, Fujii T, Matsuoka K, Yusuke E, Negi M, Takenaka K, Nagahori M, Ohtsuka K, Isobe M, Watanabe M: Endoscopic features and genetic background of inflammatory bowel disease complicated with Takayau arteritis. J Gastroenterol Hepatol. 32: 1011-1017, 2017.
    8 Nagahori M, Kochi S, Yamamoto T, Nakamura S, Omuro S, Watanabe M, Hibi T, OPTIMUM Study Group: Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol. 17: 47-59, 2017.
    9 Suzuki Y, Motoya S, Hanai H, HIbi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 52: 1031-1040, 2017.
    10 Maeyashiki C, Oshima S, Otsubo K, Kobayashi M, Nibe Y, Matsuzawa Y, Onizawa M, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Watanabe M: HADHA, the alpha subunit of the mitochondrial trifunctional protein, is involved in long-chain fatty acid-induced autophagy in intestinal epithelial cells. Biochem Biophys Res Commun. 484: 636-641, 2017.
    11 Murakawa M, Asahina Y, Nagata H, Nakagawa M, Kakinuma S, Nitta S, Kawai-Kitahata F, Otani S, Kaneko S, Miyoshi M, Tsunoda T, Asano Y, Sato A, Itsui Y, Azuma S, Nouchi T, Furumoto Y, Asano T, Chuganji Y, Tohda S, Watanabe M: ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin. Hepatol Res. 47: 1212-1218, 2017.
    12 Shinozaki M, Kobayashi K, Kunisaki R, Hisamatsu T, Naganuma M, Takahashi K, Iwao Y, Suzuki Y, Watanabe M, Itabashi M, Torii A, Takazoe M, Sugita A: Surveillance for dysplasia in patients with ulcerative colitis: discrepancy between guidelines and practice. Dig Endosc. 29: 584-593, 2017.
    13 Murakawa M, Asahina Y, Kawai-Kitahata F, Nakagawa M, Nitta S, Otani S, Nagata H, Kaneko S, Asano Y, Tsunoda T, Miyoshi M, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Iijima S, Tsuchiya K, Izumi N, Tohda S, Watanabe M: Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimutaled gene expression in chronic hepatitis C patients. J Med Virol. 89: 1241-1247, 2017.
    14 Tazuma S, Unno M, Igarashi Y, Inui K, Uchiyama K, Kai M, Tsuyuguchi T, Maguchi H, Mori T, Yamaguchi K, Ryozawa S, Nimura Y, Fujita N, Kubota K, Shoda J, Tabata M, Mine T, Sugano K, Watanabe M, Shimosegawa T: Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 52: 276-300, 2017.
    15 Nakata T, Shimizu H, Nagata S, Ito G, Fujii S, Suzuki K, Kawamoto A, Ishibashi F, Kuno R, Anzai S, Murano T, Mizutani T, Oshima S, Tsuchiya K, Nakamura T, Hozumi K, Watanabe M, Okamoto R: Indispensable role of Notch ligand-dependent signaling in the proliferation and stem cell niche maintenance of APC-deficient intestinal tumors. Biochem Biophys Res Commun. 482:1296-1303, 2017.
    16 Tsuchiya K, Hayashi R, Fukushima K, Hibiya S, Horita N, Negi M, Itoh E, Akashi T, Eishi Y, Motoya S, Takeuchi Y, Kunisaki R, Fukunaga K, Nakamura S, Yoshimura N, Takazoe M, Iizuka B, Suzuki Y, Nagahori M, Watanabe M: CDX2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis. J Gastoenterol Hepatol. 32: 1032-1039, 2017.
    17 Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Fujii T, Nagahori M, Kimura M, Fujioka T, Araki A, Watanabe M: Magnetic resonance evaluation for small bowel strictures in Crohn’s disease: comparion with balloon enteroscopy. J Gastroenterol. 52: 879-888, 2017.
    18 Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T: Leucine-rich alpha-2 glicoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohns Colitis. 11:84-91, 2017.
    19 Goto F, Kakinuma S, Miyoshi M, Tsunoda T, Kaneko S, Sato A, Asano Y, Otani S, Azuma S, Nagata H, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Nakagawa M, Asahina Y, Watanabe M: Bone morphogenetic protein-4 modulates proliferation and terminal differentiation of fetal hepatic stem/progenitor cells. Hepatol Res. 47: 941-952, 2017.
    20 Fujimoto K, Kinoshita M, Tanaka H, Okuzaki D, Shimada Y, Kayama H, Okumura R, Furuta Y, Narazaki M, Tamura A, Hatakeyama S, Ikawa M, Tsuchiya K, Watanabe M, Kumanogoh A, Tsukita S, Takeda K: Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186. Mucosal Immunol. 10: 446-459, 2017.
    21 Kuwahara E, Murakami Y, Nakamura T, Inoue N, Nagahori M, Matsui T, Watanabe M, Suzuki Y, Nishiwaki Y: Factors associtated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. J Gastroenterol. 52: 185-193, 2017.
    22 Nakamura T, Watanabe M: Intestinal stem cell transplantation. J Gastroenterol. 52: 151-157, 2017.

2016年

  • 1 Nakata T, Shimizu H, Nagata S, Ito G, Fujii S, Suzuki K, Kawamoto A, Ishibashi F, Kuno R, Anzai S, Murano T, Mizutani T, Oshima S, Tsuchiya K, Nakamura T, Hozumi K, Watanabe M, Okamoto R: Data showing proliferation and differentiation of intestinal epithelial cells under targeted depletion of Notch ligands in mouse intestine. Data Brief. 10: 551-556, 2016.
    2 Kobayashi M, Oshima S, Maeyashiki C, Nibe Y, Otsubo K, Matsuzawa Y, Memoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Watanabe M: The ubiquitin hybrid gene UBA52 regulates ubiquitination of ribosome and sustains embryonic development. Sci. Rep. 6:36780, 2016.
    3 Fujii S, Okamoto R, Suzuki K, Kawamoto A, Ishibashi F, Nakata T, Murano T, Ito G, Shimizu H, Mizutani T, Oshima S, Tsuchiya K, Nakamura T, Araki A, Ohtsuka K, Watanabe M: PGE2 is a direct and robust mediator of anion/fluid secretion by human intestinal epithelial cells. Sci. Rep. 6: 36795, 2016.
    4 Kojima T, Tsuchiya K, Ikemizu S, Yoshikawa S, Yamanishi Y, Watanabe M, Karasuyama H: Novel CD200 homologues iSEC1 and iSEC2 are gastrointestinal secretory cell-specific ligands of inhibitory receptor CD200R. Sci. Rep. 6:36457, 2016.
    5 Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, Diamond Study Group.: Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: A prospective, randomized trial. J Crohns Colitis. 10: 1259-1266, 2016.
    6 Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo S, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T: Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology.151: 1122-1130, 2016.
    7 Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Goto F, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tojo N, Tohda S, Asahina Y, Watanabe M; Ochanomizu Liver Conference Study Group: Serial measurement of wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitits C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 10: 956-964, 2016.
    8 Miyoshi M, Kakinuma S, Tanabe Y, Ishii K, Li TC, Wakita T, Tsuura Y, Watanabe H, Asahina Y, Watanabe M, Ikeda T: Chronic hepatitis E infection in a persistently immunosuppressed patient unable to be eliminated after ribarvirin therapy. Internal Medicine. 55: 2811-2817, 2016.
    9 Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T, Suzuki R, Kato N, Watanabe M, Wakita T, Kato T: Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents. Sci. Rep. 6: 34652, 2016.
    10 Matsumoto T, Mochizuki W, Nibe Y, Akiyama S, Matsumoto Y, Nozaki K, Fukuda M, Hayashi A, Mizutani T, Oshima S, Watanabe M, Nakamura T: Retinol promotes in vitro growth of proximal colon orgnaoids through a retinoic acid-independent mechanism. PLoS One. 11(8): e0162049. doi: 10.1371/journal.pone.0162049, 2016.
    11 Hosoe N, Watanabe K, Miyazaki T, Shimatani M, Wakamatsu T, Okazaki K, Esaki M, Matsumoto T, Abe T, Kanai T, Ohtsuka K, Watanabe M, Ikeda K, Tajiri H, Ohmiya N, Nakamura M, Goto H, Tsujikawa T, Ogata H: Evaluation of performance of the omnimode for detecting video capsule endoscopy images: A multicenter randomoized controlled trial. Endowc Int Open. 4: E878-E882, 2016.
    12 Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T, Nitta S, Asano Y, Nagata H, Otani S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Nakauchi H, Nishitsuji H, Ujino S, Shimotohno K, Iwamoto M, Watashi K, Wakita T, Watanabe M: Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Sci. Rep. 6: 29358, 2016.
    13 Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe M, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T: Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 51: 751-767, 2016.
    14 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T: Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 51: 629-650, 2016.
    15 Komoto S, Motoya S, Nishiwaki Y, Matsui T, Kunisaki R, Matsuoka K, Yoshimura N, Kagaya T, Naganuma M, Hida N, Watanabe M, Hibi T, Suzuki Y, Miura S, Hokari R; Japanese study group for pregnant women with IBD: Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intest Res. 14: 139-145, 2016.
    16 Taniguchi M, Tasaka-Fujita M, Nakagawa M, Watanabe T, Kawai-Kitahata F, Otani S, Goto F, Nagata H, Kaneko S, Nitta S, Murakawa M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Mori K, Yagi S, Kakinuma S, Asahina Y, Watanabe M: Evaluation of interferon resistance in newly established genotype 1b hepatitis C virus cell culture system. J Clin Transl Heptarol. 28: 5-11, 2016.
    17 Ogata H, Watanabe M, Matsui T, Hase H, Okayasu M, Tsuchiya T, Shinmura Y, Hibi T: Safety of adalimumab and predictors of adverse events in 1963 Japanese patients with Crohn’s disease. J Crohns Colitis. 10: 1033-1041, 2016.
    18 Calabrese E, Maaser C, Zorzi F, Kannengiesser K, Hanauer SB, Bruining DH, Iacucci M, Maconi G, Novak KL, Panaccione R, Strobel D, Wilson SR, Watanabe M, Pallone F, Ghosh S: Bowel ultrasonography in the management of Crohn’s disease. A review with recommendations of an international panel of experts. Inflamm Bowel Dis. 22: 1168-1183, 2016.
    19 Hayashi R, Tsuchiya K, Fukushima K, Horita N, Hibiya S, Kitagaki K, Negi M, Ito E, Akashi T, Eishi Y, Okada E, Araki A, Ohtsuka K, Fukuda S, Ohno H, Okamoto R, Nakamura T, Tanaka S, Chyayama K, Watanabe M: Reduced human α-defensin 6 in non-inflamed jejunal tissue of Crohn’s disease patients. Inflamm Bowel Dis. 22: 1119-1128, 2016.
    20 Nozaki K, Mochizuki W, Matsumoto Y, Matsumoto T, Fukuda M, Mizutani T, Watanabe M, Nakamura T: Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J Gastroenterol. 51: 206-213, 2016.
    21 Nagaishi T, Watabe T, Jose N, Tokai A, Fujii T, Matsuoka K, Nagahori M, Ohtsuka K, Watanabe M: Epithelial nuclear factor-κB activation in inflammatory bowel diseases and colitis-associated carcinogenesis. Digestion. 93:40-46, 2016.
    22 Ito T, Ishiguro H, Ohara H, Kamisawa T, Sakagami J, Sata N, Takeyama Y, Hirota M, Miyakawa H, Igarashi H, Lee L, Fujiyama T, Hijioka M, Ueda K, Tachibana Y, Sogame Y, Yasuda H, Kato R, Kataoka K, Shiratori K, Sugiyama M, Okazaki K, Kawa S, Tando Y, Kinoshita Y, Watanabe M, Shimosegawa T: Evidence-based clinical practice guidelines for chronic pancreatitis 2015. J Gastroenterol. 51: 85-92, 2016.
    23 Otani S, Kakinuma S, Kamiya A, Goto F, Kaneko S, Miyoshi M, Tsunoda T, Asano Y, Kawai-Kitahata F, Nitta S, Nakata T, Okamoto R, Itsui Y, Nakagawa M, Azuma S, Asahina Y, Yamaguchi T, Koshikawa N, Seiki M, Nakauchi H, Watanabe M: Matrix metalloproteinase-14 mediates formation of bile ducts and hepatic maturation of fetal hepatic progenitor cells. Biochem Biophys Res Commun. 469: 1062-1068, 2016.
    24 Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F, Nagata H, Kaneko S, Tasaka-Fujita M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Takano S, Fukasawa M, Sakamoto M, Maekawa S, Enomoto N, Watanabe M: Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol. 51: 473-486, 2016.
    25 Azuma S, Asahina Y, Nishimura-Sakurai Y, Kakinuma S, Kaneko S, Nagata H, Goto F, Ootani S, Kawai-Kitahata F, Taniguchi M, Murakawa M, Watanabe T, Tasaka–Fujita M, Itsui Y, Nakagawa M, Watanabe M: Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res. 46: 312-319,2016.
    26 Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T: First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 51: 241-251,2016.
    27 Okamoto R, Watanabe M: Diagnosis and treatment of microscopic colitis. Clin J Gastroenterol. 9: 169-174, 2016.
    28 Ohtsuka K, Takenaka K, Kitazume Y, Fuji T, Matsuoka K, Kimura M, Nagaishi T, Watanabe M: Magnetic resonance enterography for the evaluation of the deep small intestine in Crohn’s disease. Intest Res. 14: 120-126, 2016.
    29 Okamoto R, Watanabe M: Investigating cell therapy for inflammatory bowel disease. Expert Opin Biol Ther. 16: 1015-1023, 2016.
    30 Asahina Y, Watanabe M: Need for appropriate programs for prevention of hepatitis B infection: Lessons from the latest nationwide survey in Japan. J Gastroenterol Hepatol. 31: 12-13, 2016.
    31 Okamoto R, Watanabe M: Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 51: 11-21, 2016.

2015年

  • 1 Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, Watanabe K, Hibi T: Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology 49:1775-1783,2015.
    2 Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T: Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn’s Disease: A prospective clinical trial. Inflamm Bowel Dis. 21:2114-2122,2015.
    3 Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, Kanazawa M, Kamiya T, Sato K, Chiba T, Furuta K, Yamato S, Arakawa T, Fujiyama Y, Azuma T, Fujimoto K, Mine T, Miura S, Kinoshita Y, Watanabe M, Sugano K, Shimosegawa T: Evaluation of kampo medicine in the clinical practice guideline for irritable bowel syndrome. J Gastroenterol. 50: 817-818,2015.
    4 Matsuzawa Y, Oshima S, Takahara M, Maeyashiki C, Nemoto Y, Kobayashi M, Nibe Y, Nozaki K, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Averil Ma, Watanabe M: TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy. Autophagy 11:1052-1062,2015.
    5 Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Fujioka T, Matsuoka K, Naganuma M, Watanabe M: Correlation of the endoscopic and magnetic resonance scoring systems in the deep small intestine in Crohn’s disease. Inflamm Bowel Dis. 21:1832-1838,2015.
    6 Fukushima K, Tsuchiya K, Kano Y, Horita N, Hibiya S, Hayashi R, Kitagaki K, Negi M, Itoh E, Akashi T, Eishi Y, Oshima S, Nagaishi T, Ryuichi O, Nakamura T, Watanabe M: Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Sci. 106:1000-1007,2015.
    7 Murakawa M, Asahina Y, Nakagawa M, Sakamoto N, Nitta S, Kusano-Kitazume A, Watanabe T, Kawai-Kitahata F, Otani S, Taniguchi M, Goto F, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M: Impaired induction of IL28B and expression of IFNλ4 associated with non-response to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol. 30:1075-1084,2015.
    8 Tanaka S, Saitoh Y, Matsuda T, Igarashi M, Matsumoto T, Iwao Y, Suzuki Y, Nishida H, Watanabe T, Sugai T, Sugihara K, Tsuruta O, Hirata I, Hiwatashi N, Saito H, Watanabe M, Sugano K, Shimosegawa T: Evidence-based clinical practice guidelines for management of colorectal polyps. J Gastroenterol. 50:252-260,2015.
    9 Asthana AK, Friedman AB, Maconi G, Maaser C, Kucharzik T, Watanabe M, Gibson PR: The failure of gastroenterologists to apply intestinal ultrasound in inflammatory bowel disease in the Asia-Pacific: A need for action. J Gastroenterol Hepatol. 30:446-452,2015.
    10 Matsuzawa Y, Oshima S, Nibe Y, Kobayashi M, Maeyashiki C, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Watanabe M: RIPK3 regulates p62-LC3 complex formation via the caspase-8-dependent cleavage of p62. Biochem Biophys Res Commun. 456:298-304,2015.
    11 Yoshida M, Kinoshita Y, Watanabe M, Sugano K: JSGE Clinical Practice Guidelines 2014: standards, methods, and process of developing the guidelines. J Gastroenterol.50:4-10,2015.
    12 Kawa S, Okazaki K, Notohara K, Watanabe M, Shimosegawa T; Study Group for Pancreatitis Complicated with Inflammatory Bowel Disease: Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis. J Gastroenterol. 50:805-815,2015.
    13 Oryoji D, Hisamatsu T, Tsuchiya K, Umeno J, Ueda S, Yamamoto K, Matsumoto T, Watanabe M, Hibi T, Sasazuki T: Associations of HLA class I alleles in Japanese patients with Crohn’s disease. Genes Immun. 16:54-56,2015.
    14 Okamoto R, Watanabe M: Perspective for regenerative medicine in inflammatory bowel diseases. Digestion. 92: 73-77, 2015.
    15 Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M: Tacrolimus for the treatment of ulcerative colitis. Intest Res. 13: 219-226, 2015.
    16 Watanabe M: Recent dramatic evolution of the Journal of Gastroenterology (JG): a note from current Editorial Director and former Editor-in-Chief of JG. J Gastroenterol. 50: 249-251, 2015.

2014年

  • 1 Kano Y, Kakinuma S, Goto F, Azuma S, Nishimura-Sakurai Y, Itsui Y, Nakagawa M, Kudo A, Tanabe M, Kirimura S, Amano T, Ito T, Akashi T, Asahina Y, Watanabe M: Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule. Clin J Gastroenterol. 7:449-454,2014.
    2 Horita N, Tsuchiya K, Hayashi R, Fukushima K, Hibiya S, Fukuda M, Kano Y, Mizutani T, Nemoto Y, Yui S, Okamoto R, Nakamura T, Watanabe M: Fluorescent labelling of intestinal epithelial cells reveals independent long-lived intestinal stem cells in a crypt. Biochem Biophys Res Commun. 454:493-499,2014.
    3 Ohfuji S, Fukushima W, Watanabe K, Sasaki S, Yamagami H, Nagahori M, Watanabe M, Hirota Y; Japanese Case-Control Study Group for Ulcerative Colitis: Pre-illness isoflavone consumption and disease risk of ulcerative colitis: a multicenter case-control study in Japan. PLoS One. 9: e110270, 2014. doi: 10.1371/journal.pone.0110270.
    4 Fukuda M, Mizutani T, Mochizuki W, Matsumoto T, Nozaki K, Sakamaki Y, Ichinose S, Okada Y, Tanaka T, Watanabe M, Nakamura T: Small intestinal stem cell identity is maintained with functional Paneth cells in heterotopically grafted epithelium onto the colon. Genes Dev. 28:1752-1757,2014.
    5 Kobayashi K, Hirai F, Naganuma M, Watanabe K, Ando T, Nakase H, Matsuoka K, Watanabe M: A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings. J Crohns Colitis. 8:1444-1453,2014.
    6 Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, Petersson J, Thakkar R: Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn’s disease. J Crohns Colitis. 8:1407-1416,2014.
    7 Shimizu H, Okamoto R, Ito G, Fujii S, Nakata T, Suzuki K, Murano T, Mizutani T, Tsuchiya K, Nakamura T, Hozumi K, Watanabe M: Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine. PeerJ 2: e370; DOI 10.7717/peerj.370,2014.
    8 Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Naganuma M, Araki A, Watanabe M: Comparison of magnetic resonance and balloon enteroscopic examination of deep small intestine in patients with Crohn’s disease. Gastroenterology. 147:334-342,2014.
    9 Suzuki M, Nagaishi T, Yamazaki M, Onizawa M, Watabe T, Sakamaki Y, Ichinose S, Totsuka M, Oshima S, Okamoto R, Shimonaka M, Yagita H, Nakamura T, Watanabe M: Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the development of colitis-associated carcinogenesis. PLoS One. 9: e88369,2014.
    10 Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, Thakkar RB, Watanabe M: Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 49:283-294,2014.
    11 Esaki M, Matsumoto T, Watanabe K, Arakawa T, Naito Y, Matsuura M, Nakase H, Hibi T, Matsumoto T, Nouda S, Higuchi K, Ohmiya N, Goto H, Kurokawa S, Motoya S, Watanabe M: Use of capsule endoscopy in patients with Crohn’s disease in Japan: A multicenter survey. J Gastroenterol Hepatol. 29:96-101,2014.
    12 Murano T, Okamoto R, Ito G, Nakata T, Hibiya S, Shimizu H, Fujii S, Kano Y, Mizutani T, Yui S, Akiyama-Morio J, Nemoto Y, Tsuchiya K, Nakamura T, Watanabe M: Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells. Biochem Biophys Res Commun. 443: 840-846,2014.
    13 Fukata N, Okazaki K, Omiya M, Matsushita M, Watanabe M; Members of the Ministry of Health and Welfare of Japan’s Inflammatory Bowel Diseases Study Group: Hematologic malignancies in Japanese patients with inflammatory bowel disease. J Gastroenterol. 49:1299-1306,2014.
    14 Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N: Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol. 49:1152-1162,2014.
    15 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, Yoshinari T, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T: C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol. 49:254-262,2014.
    16 Watanabe K, Sasaki I, Fukushima K, Futami K, Ikeuchi H, Sugita A, Nezu R, Mizushima T, Kameoka S, Kusunoki M, Yoshioka K, Funayama Y, Watanabe T, Fujii H, Watanabe M; Surgical Research Group, Research Committee of Inflammatory Bowel Disease, Ministry of Health, Labour and Welfare of Japan: Long-term incidence and characteristics of intestinal failure in Crohn’s disease: A Japanese multicenter study. J Gastroenterol. 49:231-238,2014.
    17 Hisabe T, Hirai F, Matsui T, Watanabe M: Evaluation of diagnostic criteria for Crohn’s disease in Japan. J Gastroenterol. 49:93-99,2014.
    18 Araki A, Tsuchiya K, Watanabe M: Advances in balloon endoscopes. Clin J Gastroenterol. 7:189-199,2014.
    19 Watanabe M: Adult tissue stem cell therapy for gastrointestinal diseases. J Gastroenterol. [Epub ahead of print],2014.
    20 Saito E, Nagahori M, Fujii T, Otsuka K, Watanabe M: Efficacy of salvage therapy and its effect on operative outcomes in patients with ulcerative colitis. Digestion. 89:55-60,2014.
    21 Fujii T, Naganuma M, Kitazume Y, Saito E, Nagahori M, Ohtsuka K, Watanabe M: Advancing magnetic resonance imaging in Crohn’s disease. Digestion. 89:24-30,2014.

2013年

  • 1 Ito G, Okamoto R, Murano T, Shimizu H, Fujii S, Nakata T, Mizutani T, Yui S, Akiyama-Morio J, Nemoto Y, Okada E, Araki A, Ohtsuka K, Tsuchiya K, Nakamura T, Watanabe M: Lineage-specific expression of Bestrophin-2 and Bestrophin-4 in human intestinal epithelial cells. PLoS One. 8: e79693,2013.
    2 Fordham RP, Yui S, Hannan NRF, Madgwick A, Vallier L, Pedersen RA, Nakamura T, Watanabe M, Jensen KB: Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell 13:734-744,2013.
    3 Takahara M, Nemoto Y, Oshima S, Matsuzawa Y, Kanai T, Okamoto R, Tsuchiya K, Nakamura T, Yamamoto K, Watanabe M: IL-7 promotes long-term in vitro survival of unique long-lived memory subset generated from mucosal effector memory CD4+ T cells in chronic colitis mice. Immunol Lett. 156:82-93,2013.
    4 Nemoto Y, Kanai T, Takahara M, Oshima S, Okamoto R, Tsuchiya K, Matsumoto S, Watanabe M: Th1/Th17-Mediated Interstitial Pneumonia in Chronic Colitis Mice Independent of Intestinal Microbiota. J Immunol. 190:6616-6625,2013.
    5 Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, Suzuki Y: Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study. Inflamm Bowel Dis. 19:1681-1690,2013.
    6 Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N: α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 58:1253-1262,2013.
    7 Kiyohashi K, Kakinuma S, Kamiya A, Sakamoto N, Nitta S, Yamanaka H, Yoshino K, Fijiki J, Murakawa M, Kusano-Kitazume A, Shimizu H, Okamoto R, Azuma S, Nakagawa M, Asahina Y, Tanimizu N, Kikuchi A, Nakauchi H, Watanabe M: Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells. Hepatology. 57:2502-2513,2013.
    8 Okada E, Araki A, Suzuki S, Morio Akiyama J, Fujii T, Okamoto R, Watanabe M: Histological diagnosis of follicular lymphoma by biopsy of small intestinal normal mucosa. Dig Endosc. 25:544-546,2013.
    9 Kano Y, Tsuchiya K, Zheng X, Horita N, Fukushima K, Hibiya S, Yamauchi Y, Nishimura T, Hinohara K, Gotoh N, Suzuki S, Okamoto R, Nakamura T, Watanabe M: The acquisition of malignant potential in colon cancer is regulated by the stabilization of Atonal homolog 1 protein. Biochem Biophys Res Commun. 432:175-181,2013.
    10 Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Tokunaga K, Mizokami M, Izumi N: Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol. 85:449-458,2013.
    11 Ohyagi M, Ohkubo T, Yagi Y, Ishibashi S, Akiyama J, Nagahori M, Watanabe M, Yokota T, Mizusawa H: Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with Crohn’s disease. Intern Med. 52:125-128,2013.
    12 Nemoto Y, Kanai T, Takahara M, Oshima S, Nakamura T, Okamoto R, Tsuchiya K, Watanabe M: Bone-marrow mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4+ memory T cells. Gut. 62:1142-1152,2013.
    13 Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T, on behalf of the Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease granted by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology: Evidence-Based Clinical Practice Guidelines for Crohn’s Disease, Integrated with Formal Consensus of Experts in Japan. J Gastroenterol. 48:31-72,2013.
    14 Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M: A prospective analysis of the incidence and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol. 48:595-560,2013.
    15 Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M: Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immunity. Hepatology. 57:46-58,2013.
    16 Kuwahara E, Asakura K, Nishiwaki Y, Inoue N, Watanabe M, Hibi T, Takebayashi T: Reply to the letter by A. M. Bianco et al. regarding ”Effects of family history on IBD characteristics in Japanese patients”. J Gastroenterol. 48:145-146,2013.
    17 Naganuma M, Fujii T, Kunisaki R, Yoshimura N, Takazoe M, Takeuchi Y, Saito E, Nagahori M, Asakura K, Takebayashi T, Watanabe M: Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients. J Crohn’s Colitis. 7:308-313,2013.
    18 Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M: Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 19:418-422,2013.
    19 Watanabe M, Nishino H, Samejima Y, Ota A, Nakamura S, Hibi T: Randomised clinical trial: Evaluation of the efficacy of mesalazine suppositories in active ulcerative colitis patients with rectal inflammation – a placebo-controlled study. Aliment Pharm Ther. 38:264-273,2013.
    20 Asahina Y, Nakagawa M, Kakinuma S, Watanabe M: Polymorphism near the interleukin 28B gene and anti-hepatitis C viral response. J Clin Trans Hepatol. 1:39-44,2013.

2012年

  • 1 Nakagawa M, Sakamoto N, Watanabe T, Nishimura-Sakurai Y, Onozuka I, Azuma S, Kakinuma S, Nitta S, Kiyohashi K, Kusano-Kitazume A, Murakawa M, Yoshino K, Itsui Y, Tanaka Y, Mizokami M, Watanabe M, Ochanomizu Liver Conference Study Group: Association of ITPA gene variant and serum ribavirin concentration with blood cells decline in pegylated interferon-alfa plus ribavirin therapy for chronic hepatitis C. Hepatol Int. 7:153-161,2012.
    2 Araki A, Suzuki S, Tsuchiya K, Oshima S, Okada E, Watanabe M: Modified Single-operator method for double-balloon endoscopy. Dig Endosc. 24:470-474,2012.
    3 Araki A, Tsuchiya K, Oshima S, Okada E, Suzuki S, Morio Akiyama J, Fujii T, Okamoto R, Watanabe M: Endoscopic ultrasound with double-balloon endoscopy for the diagnosis of inverted Meckel’s diverticulum: a case report. J Med Case Rep. 6:328,2012.
    4 Ono Y, Kanai T, Sujino T, Nemoto Y, Kanai Y, Mikami Y, Hayashi A, Matsumoto A, Takaishi H, Ogata H, Matsuoka K, Hisamatsu T, Watanabe M, Hibi T: T-helper 17 and interleukin-17-producing lymphoid tissue inducer-like cells make different contributions to colitis in mice. Gastroenterology. 143:1288-1297,2012.
    5 Kuwahara E, Asakura K, Nishiwaki Y, Inoue N, Watanabe M, Hibi T, Takebayashi T: Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 47:961-968,2012.
    6 Watanabe T, Sasaki I, Sugita A, Fukushima K, Futami K, Hibi T, Watanabe M: Time trend and risk factors for reoperation in Crohn’s disease in Japan. Hepatogastroenterology. 59:1081-1086,2012.
    7 Fujita K, Naganuma M, Saito E, Suzuki S, Araki A, Negi M, Kawachi H, Watanabe M: Histologically confirmed IgG4-related small intestinal lesions diagnosed via double balloon enteroscopy. Dig Dis Sci. 57:3303-3306,2012.
    8 Mizutani T, Nakamura T, Morikawa R, Fukuda M, Mochizuki W, Yamauchi Y, Nozaki K, Yui S, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Watanabe M: Real-time analysis of P-glycoprotein-mediated drug transport across primary intestinal epithelium three-dimensionally cultured in vitro. Biochem Biophys Res Commun. 419:238-243,2012.
    9 Yamaji O, Nagaishi T, Totsuka T, Onizawa M, Suzuki M, Tsuge N, Hasegawa A, Okamoto R, Tsuchiya K, Nakamura T, Arase H, Kanai T, Watanabe M: The development of colitogenic CD4+ T cells is regulated by IL-7 in collaboration with natural killer cell function in a murine model of colitis. J Immunol. 188:2524-2536,2012.
    10 Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyohashi K, Nitta S, Murakawa M, Azuma S, Nishimura-Sakurai Y, Hagiwara M, Watanabe M: Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. Antimicrob Agents Chemother. 56:1315-1323,2012.
    11 Yui S, Nakamura T, Sato T, Nemoto Y, Mizutani T, Zheng X, Ichinose S, Nagaishi T, Okamoto R, Tsuchiya K, Clevers H, Watanabe M: Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell. Nat Med. 18:618-623,2012.
    12 Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam SS, Camez A: Adalimumab for the Induction and Maintenance of Clinical Remission in Japanese patients with Crohn’s Disease. J Crohns Colitis. 6:160-173,2012.
    13 Watanabe T, Sasaki I, Sugita A, Fukushima K, Futami K, Hibi T, Watanabe M: Interval of less than 5 years between the first and second operation is a risk factor for a third operation for Crohn’s disease. Inflamm Bowel Dis. 18:17-24,2012.
    14 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T: Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn’s disease. Inflamm Bowel Dis. 18:1480-1487,2012.

2011年

  • 1 Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi H, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, Ajioka Y, Hibi T, Watanabe M, Muto T, Nagawa H: Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis. Clin Colorectal Cancer. 10:134-141,2011.
    2 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N: Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One. 6: e24514,2011.
    3 Nemoto Y, Kanai T, Shinohara T, Ito T, Nakamura T, Okamoto R, Tsuchiya K, Lipp M, Eishi Y, Watanabe M: Luminal CD4+ T cells penetrate gut epithelial monolayers and egress from lamina propria to blood circulation. Gastroenterology. 141:2130-2139,2011.
    4 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N: Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. Hepatol Int. 5:789-799,2011.
    5 Naganuma M, Kunisaki R, Yoshimura N, Nagahori M, Yamamoto H, Kimura H, Sako M, Kawaguchi T, Takazoe M, Yamamoto S, Matsui T, Hibi T, Watanabe M: Conception and pregnancy outcome in women with inflammatory bowel disease: A multicentre study from Japan. J Crohns Colitis. 5:317-323,2011.
    6 Funaoka Y, Sakamoto N, Nakagawa M, Kakinuma S, Suda G, Watanabe T, Nitta S, Kitazume A, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Watanabe M: Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol. 85:5986-5994,2011.
    7 Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M: Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin. Antiviral Therapy. 16:1081-1091,2011.
    8 Onozuka I, Kakinuma S, Kamiya A, Miyoshi M, Sakamoto N, Kiyohashi K, Watanabe T, Funaoka Y, Ueyama M, Nakagawa M, Koshikawa N, Seiki M, Nakauchi H, Watanabe M: Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem Biophys Res Commun. 406:134-140,2011.
    9 Watanabe T, Kobunai T, Ikeuchi H, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, Ajioka Y, Hibi T, Watanabe M, Muto T, Nagawa H: RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol. 38:201-207,2011.
    10 Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Hige S, Ito Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M: Association of IL28B polymorphism with response to pegylated-interferon alpha plus ribavirin combination therapy in patients with chronic genotype 2 hepatitis C. J Med Virol. 83:871-878,2011.
    11 Shinohara T, Nemoto Y, Kanai T, Kameyama K, Okamoto R, Tsuchiya K, Nakamura T, Totsuka T, Ikuta K, Watanabe M: Upregulated IL-7Rα expression on colitogenic memory CD4+ T cells may participate in the development and persistence of chronic colitis. J Immunol. 186:2623-2632,2011.
    12 Yamamoto M, Sakamoto N, Nakamura T, Itsui Y, Nakagawa M, Nishimura-Sakurai Y, Kakinuma S, Azuma S, Tsuchiya K, Kato T, Wakita T, Watanabe M: Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture. Hepatology Res. 41:258-269,2011.
    13 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? Am J Gastroenterol. 106:199-212,2011.
    14 Zheng X, Tsuchiya K, Okamoto R, Iwasaki M, Kano Y, Sakamoto N, Nakamura T, Watanabe M: Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 17:2251-2260,2011.
    15 Iwasaki M, Tsuchiya K, Okamoto R, Zheng X, Kano Y, Okamoto E, Okada E, Araki A, Suzuki S, Sakamoto N, Kitagaki K, Akashi T, Eishi Y, Nakamura T, Watanabe M: Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4. J Gastroenterol. 46:191-202,2011.
    16 Kurosaki M, Tanaka Y, Nishida N, Sugiyama M, Matsuura K, Asahina Y, Sugauchi F, Sakamoto N, Nakagawa M, Watanabe M, Sakai A, Honda M, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M: Pre-treatment prediction of response to pegylated-Interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 54:439-448,2011.
    17 Naganuma M, Fujii T, Watanabe M: The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 46:129-137,2011.
    18 Watanabe T, Ajioka Y, Matsumoto T, Tomotsugu N, Takebayashi T, Inoue E, Iizuka B, Igarashi M, Iwao Y, Ohtsuka K, Kudo SE, Kobayashi K, Sada M, Matsumoto T, Hirata I, Murakami K, Nagahori M, Watanabe K, Hida N, Ueno F, Tanaka S, Watanabe M, Hibi T: Target biopsy or step biopsy? Optimal surveillance for ulcerative colitis: a Japanese nationwide randomized controlled trial. J Gastroenterol. 1:11-16,2011.
    19 Naganuma M, Watanabe M, Hibi T: Safety and usefulness of balloon endoscopy in Crohn’s disease patients with postoperative ileal lesions. J Crohns Colitis. 5:73-74,2011.

2010年以前はこちら